Concepedia

Author

Douglas L. Mayers

Idera Pharmaceuticals (United States)

Also Known As

Chrissie Matiki, D L Mayers, D Mayers, D. L. Mayers, D. Mayers, D.L. Mayers, DOUGLAS L. MAYERS, Douglas L Mayers, Douglas L. Mayers, Douglas Mayers

124

Publications

6.7K

Citations

36

H-Index

67

Concepts

All Affiliations

Idera Pharmaceuticals (United States)Boehringer Ingelheim (United States)Walter Reed Army Institute of ResearchNaval Medical Research CommandBoehringer Ingelheim (Germany)
DL

About

Douglas L. Mayers is an author at Idera Pharmaceuticals (United States) specializing in medicine, hiv, and virology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

23

31

3.8K

2

Public Health

3

3

316

3

Health Sciences

2

2

559

4

Natural Sciences

2

2

109

5

Engineering

1

1

16

Douglas L. Mayers

×

62

Publications

6.2K

Citations

34

H-Index

YearCitations

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Travis K. Warren, Robert Jordan, Michael K. Lo,

Nature

2016

1.6K

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy

John D. Baxter, Douglas L. Mayers, Deborah Wentworth,

AIDS

2000

502

Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

Charles B. Hicks, Pedro Cahn, David A. Cooper,

The Lancet

2006

322

Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group

A J Japour, Douglas L. Mayers, Victoria A. Johnson,

Antimicrobial Agents and Chemotherapy

1993

294

Structured Treatment Interruption in Patients with Multidrug-Resistant Human Immunodeficiency Virus

Jody Lawrence, Douglas L. Mayers, Katherine Huppler Hullsiek,

New England Journal of Medicine

2003

265

Two-dimensional echocardiographic measurement of left ventricular ejection fraction: Prospective analysis of what constitutes an adequate determination

R. Brad Stamm, Blasé A. Carabello, Douglas L. Mayers,

American Heart Journal

1982

255

Primary Infection with Zidovudine-Resistant Human Immunodeficiency Virus Type 1

Alejo Erice, Douglas L. Mayers, David G. Strike,

New England Journal of Medicine

1993

244

A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients*

Jerry O. Stern, Patrick Robinson, James E. Love,

JAIDS Journal of Acquired Immune Deficiency Syndromes

2003

237

Antiviral Effect and Ex Vivo CD4 <sup>+</sup> T Cell Proliferation in HIV-Positive Patients as a Result of CD28 Costimulation

Bruce L. Levine, Joseph D. Mosca, James L. Riley,

Science

1996

220

Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use

Horacio Salomón, Mark A. Wainberg, Bluma Brenner,

AIDS

2000

203

Page 1